Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Saga To Block Sage Pharmaceuticals Shows Enforcement Challenges

This article was originally published in The Tan Sheet

Executive Summary

After at least eight warning letters and a previous injunction over a decade failed to stop Sage Pharmaceuticals from allegedly making and distributing misbranded and unapproved OTC and Rx drugs, FDA is taking another run at the firm via a DoJ suit. The firm’s disregard of previous warnings underscores the challenges FDA must overcome to become an effective enforcer.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts